MetaVia announces completion of Phase 1 Part 3A study trend.
MetaVia Inc. reported positive interim Part 3B results and the completion of a recently extended Phase 1 trial for its DA-1726 drug candidate, supporting a planned Phase 2 launch.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed